| Year |
Citation |
Score |
| 2015 |
Chase TN, Clarence-Smith K. P1-290: High-dose cholinesterase inhibitor treatment of Alzheimer's disease Alzheimer's & Dementia. 11: P466-P467. DOI: 10.1016/J.Jalz.2015.06.491 |
0.3 |
|
| 2008 |
Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacology, Biochemistry, and Behavior. 90: 540-4. PMID 18534670 DOI: 10.1016/J.Pbb.2008.04.010 |
0.4 |
|
| 2007 |
Liang ZQ, Wang X, Li LY, Wang Y, Chen RW, Chuang DM, Chase TN, Qin ZH. Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum. Journal of Neuroscience Research. 85: 1295-309. PMID 17385714 DOI: 10.1002/Jnr.21248 |
0.321 |
|
| 2007 |
Smith CP, Oh JD, Bibbiani F, Collins MA, Avila I, Chase TN. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology. 52: 515-26. PMID 17116309 DOI: 10.1016/J.Neuropharm.2006.08.018 |
0.635 |
|
| 2006 |
Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1380-3. PMID 16758479 DOI: 10.1002/Mds.20976 |
0.411 |
|
| 2005 |
Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental Neurology. 196: 422-9. PMID 16203001 DOI: 10.1016/J.Expneurol.2005.08.017 |
0.674 |
|
| 2005 |
Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 932-6. PMID 15791634 DOI: 10.1002/Mds.20370 |
0.472 |
|
| 2004 |
Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 1183-6. PMID 15390018 DOI: 10.1002/Mds.20124 |
0.433 |
|
| 2004 |
Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology. 47: 184-94. PMID 15223297 DOI: 10.1016/J.Neuropharm.2004.03.011 |
0.684 |
|
| 2004 |
Chase TN. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism & Related Disorders. 10: 305-13. PMID 15196510 DOI: 10.1016/j.parkreldis.2004.02.012 |
0.343 |
|
| 2004 |
Duan Y, Lipkovich I, Ahmed S, Ahl J, Hardy T, Haldane D, Baker R, Tohen M, Liu-Seifert H, Healey K, Kinon BJ, Ahmed S, Lipkovich IA, Tohen MF, Hoffmann V, ... ... Chase T, ... ... Chase TN, et al. Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 Neurorx. 1: 506-514. DOI: 10.1602/Neurorx.1.4.506 |
0.531 |
|
| 2003 |
Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology. 61: S107-11. PMID 14663022 |
0.35 |
|
| 2003 |
Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology. 184: 285-94. PMID 14637099 DOI: 10.1016/S0014-4886(03)00250-4 |
0.679 |
|
| 2003 |
Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotoxicity Research. 5: 139-46. PMID 12832228 DOI: 10.1007/Bf03033378 |
0.682 |
|
| 2003 |
Blanchet PJ, Konitsiotis S, Mochizuki H, Pluta R, Emerich DF, Chase TN, Mouradian MM. Complications of a trophic xenotransplant approach in parkinsonian monkeys. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 607-12. PMID 12787846 DOI: 10.1016/S0278-5846(03)00048-4 |
0.317 |
|
| 2003 |
Oh JD, Chartisathian K, Ahmed SM, Chase TN. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. Journal of Neuroscience Research. 72: 768-80. PMID 12774317 DOI: 10.1002/Jnr.10629 |
0.668 |
|
| 2003 |
Oh JD, Geller AI, Zhang Gr, Chase TN. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Research. 971: 18-30. PMID 12691833 DOI: 10.1016/S0006-8993(03)02348-5 |
0.648 |
|
| 2003 |
Schwarzschild MA, Chen JF, Chase TN. A2A antagonists for PD: A prime example of translational neuroscience Neurology. 61: S3-S4. DOI: 10.1212/01.Wnl.0000095202.94814.0F |
0.38 |
|
| 2002 |
Oh JD, Bibbiani F, Chase TN. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Experimental Neurology. 177: 557-64. PMID 12429201 DOI: 10.1006/Exnr.2002.8009 |
0.695 |
|
| 2002 |
Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, Weinberger DR, Mattay VS. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 9099-103. PMID 12388617 DOI: 10.1523/Jneurosci.22-20-09099.2002 |
0.346 |
|
| 2002 |
Oh JD, Chase TN. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids. 23: 133-9. PMID 12373527 DOI: 10.1007/s00726-001-0118-2 |
0.666 |
|
| 2002 |
Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 59: 694-9. PMID 12221159 |
0.342 |
|
| 2002 |
Jeffries KJ, Schooler C, Schoenbach C, Herscovitch P, Chase TN, Braun AR. The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 92-104. PMID 12062910 DOI: 10.1016/S0893-133X(01)00428-6 |
0.326 |
|
| 2002 |
Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Annals of Neurology. 51: 156-64. PMID 11835371 DOI: 10.1002/Ana.10078 |
0.367 |
|
| 2001 |
Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 57: 1829-34. PMID 11723272 DOI: 10.1212/Wnl.57.10.1829 |
0.653 |
|
| 2001 |
Chase TN, Konitsiotis S, Oh JD. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Advances in Neurology. 86: 355-60. PMID 11553996 |
0.607 |
|
| 2001 |
Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 515-20. PMID 11391748 DOI: 10.1002/Mds.1112 |
0.446 |
|
| 2001 |
Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 459-63. PMID 11391739 DOI: 10.1002/Mds.1085 |
0.328 |
|
| 2001 |
Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clinical Neuropharmacology. 24: 163-9. PMID 11391128 DOI: 10.1097/00002826-200105000-00008 |
0.305 |
|
| 2000 |
Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends in Neurosciences. 23: S86-91. PMID 11052225 DOI: 10.1016/S1471-1931(00)00018-5 |
0.641 |
|
| 2000 |
Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Journal of Neurology. 247: II36-42. PMID 10991664 DOI: 10.1007/Pl00007759 |
0.66 |
|
| 2000 |
Marin C, Jimenez A, Bonastre M, Chase TN, Tolosa E. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse (New York, N.Y.). 36: 267-74. PMID 10819904 DOI: 10.1002/(Sici)1098-2396(20000615)36:4<267::Aid-Syn3>3.0.Co;2-Y |
0.467 |
|
| 2000 |
Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54: 1589-95. PMID 10762498 DOI: 10.1212/Wnl.54.8.1589 |
0.443 |
|
| 2000 |
Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Annals of Neurology. 47: S122-9; discussion S. PMID 10762139 |
0.672 |
|
| 2000 |
Nakai M, Qin ZH, Chen JF, Wang Y, Chase TN. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. Journal of Neurochemistry. 74: 647-58. PMID 10646516 DOI: 10.1046/J.1471-4159.2000.740647.X |
0.359 |
|
| 2000 |
Oh JD, Chartisathian K, Chase TN, Butcher LL. Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain. Brain Research. 853: 174-85. PMID 10640615 DOI: 10.1016/S0006-8993(99)02054-5 |
0.582 |
|
| 2000 |
Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 3-8. PMID 10634235 DOI: 10.1002/1531-8257(200001)15:1<3::Aid-Mds1003>3.0.Co;2-E |
0.385 |
|
| 1999 |
Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::Aid-Mds1001>3.0.Co;2-H |
0.381 |
|
| 1999 |
Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Archives of Neurology. 56: 1383-6. PMID 10555659 DOI: 10.1001/Archneur.56.11.1383 |
0.379 |
|
| 1999 |
Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. The Journal of Pharmacology and Experimental Therapeutics. 290: 1034-40. PMID 10454475 |
0.306 |
|
| 1999 |
Oh JD, Vaughan CL, Chase TN. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Research. 821: 433-42. PMID 10064831 DOI: 10.1016/S0006-8993(99)01121-X |
0.647 |
|
| 1999 |
Oh JD, Russell DS, Vaughan CL, Chase TN. Corrigendum to: Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration Brain Research. 820: 117. PMID 10023039 DOI: 10.1016/S0006-8993(99)01053-7 |
0.609 |
|
| 1998 |
Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14: 75-82. PMID 9871445 DOI: 10.1007/BF01345246 |
0.324 |
|
| 1998 |
Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clinical Neuropharmacology. 21: 339-43. PMID 9844789 |
0.338 |
|
| 1998 |
Oh JD, Russell DS, Vaughan CL, Chase TN, Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Research. 813: 150-9. PMID 9824689 DOI: 10.1016/S0006-8993(98)01049-X |
0.639 |
|
| 1998 |
Blanchet PJ, Konitsiotis S, Hyland K, Arnold LA, Pettigrew KD, Chase TN. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Experimental Neurology. 153: 214-22. PMID 9784281 DOI: 10.1006/Exnr.1998.6906 |
0.38 |
|
| 1998 |
Fahn S, Clarence-Smith KE, Chase TN. Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions--report of a workshop. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 759-67. PMID 9756143 DOI: 10.1002/Mds.870130502 |
0.307 |
|
| 1998 |
Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology. 51: S30-5. PMID 9711978 DOI: 10.1212/Wnl.51.2_Suppl_2.S30 |
0.689 |
|
| 1998 |
Verhagen Metman L, Del Dotto P, Natté R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 51: 203-6. PMID 9674803 |
0.357 |
|
| 1998 |
Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natté R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 414-7. PMID 9613730 DOI: 10.1002/Mds.870130307 |
0.419 |
|
| 1998 |
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50: 1323-6. PMID 9595981 |
0.33 |
|
| 1998 |
Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 50: S17-25. PMID 9591518 DOI: 10.1212/Wnl.50.5_Suppl_5.S17 |
0.457 |
|
| 1998 |
Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 55: 1-9. PMID 9483164 |
0.39 |
|
| 1997 |
Blanchet PJ, Konitsiotis S, Chase TN. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. The Journal of Pharmacology and Experimental Therapeutics. 283: 794-9. PMID 9353400 |
0.338 |
|
| 1997 |
Chase TN. A gene for Parkinson disease. Archives of Neurology. 54: 1156-7. PMID 9311360 DOI: 10.1001/Archneur.1997.00550210084017 |
0.303 |
|
| 1997 |
Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neuroscience Letters. 228: 5-8. PMID 9197274 DOI: 10.1016/S0304-3940(97)00355-8 |
0.678 |
|
| 1997 |
Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neuroscience and Biobehavioral Reviews. 21: 447-53. PMID 9195602 DOI: 10.1016/S0149-7634(96)00038-3 |
0.358 |
|
| 1997 |
Mouradian MM, Chase TN. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications. Experimental Neurology. 144: 51-7. PMID 9126152 DOI: 10.1006/Exnr.1996.6388 |
0.459 |
|
| 1997 |
Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 48: 369-72. PMID 9040723 |
0.305 |
|
| 1996 |
Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Research. 736: 202-5. PMID 8930325 DOI: 10.1016/0006-8993(96)00693-2 |
0.357 |
|
| 1996 |
Blesa R, Mohr E, Miletich RS, Hildebrand K, Sampson M, Chase TN. Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Dementia (Basel, Switzerland). 7: 239-45. PMID 8872413 DOI: 10.1159/000106886 |
0.309 |
|
| 1996 |
Marin C, Engber TM, Chaudhuri P, Peppe A, Chase TN. Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors. Psychopharmacology. 123: 215-21. PMID 8741947 DOI: 10.1007/Bf02246181 |
0.398 |
|
| 1996 |
Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 257-60. PMID 8723141 DOI: 10.1002/mds.870110307 |
0.339 |
|
| 1996 |
Anderson JJ, Kask AM, Chase TN. Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. European Journal of Pharmacology. 295: 163-8. PMID 8720580 DOI: 10.1016/0014-2999(95)00661-3 |
0.402 |
|
| 1996 |
Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Annals of Neurology. 39: 574-8. PMID 8619541 DOI: 10.1002/Ana.410390505 |
0.434 |
|
| 1995 |
Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Research. 701: 13-8. PMID 8925275 DOI: 10.1016/0006-8993(95)00924-3 |
0.388 |
|
| 1995 |
Boldry RC, Papa SM, Kask AM, Chase TN. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior. Brain Research. 692: 259-64. PMID 8548312 DOI: 10.1016/0006-8993(95)00690-R |
0.395 |
|
| 1995 |
Anderson JJ, Randall S, Chase TN. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum. The Journal of Pharmacology and Experimental Therapeutics. 274: 928-36. PMID 7636756 |
0.319 |
|
| 1995 |
Chase TN, Metman LV, Bravi D, Roberts JW, Sibley DR, Mouradian MM. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease Clinical Neuropharmacology. 18: S207-S215. DOI: 10.1097/00002826-199501001-00022 |
0.419 |
|
| 1995 |
Mierau J, Bedard PJ, Van Tol, Willner P, Schatzberg, Piercey MF, Chase TN, Sethy, Ranhosky. Pramipexole: A dopamine-receptor agonist for treatment of Parkinson's disease Clinical Neuropharmacology. 18: S195-S206. |
0.314 |
|
| 1994 |
Blin J, Ray CA, Piercey MF, Bartko JJ, Mouradian MM, Chase TN. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography. Brain Research. 635: 196-202. PMID 8173955 DOI: 10.1016/0006-8993(94)91439-7 |
0.318 |
|
| 1994 |
Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Annals of Neurology. 36: 27-31. PMID 8024257 DOI: 10.1002/ana.410360108 |
0.355 |
|
| 1994 |
Metman LV, Sethy VH, Roberts JR, Bravi D, Hoff JI, Mouradian MM, Chase TN. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 577-81. PMID 7990854 DOI: 10.1002/mds.870090512 |
0.314 |
|
| 1994 |
Oyanagi K, Makifuchi T, Ohtoh T, Chen KM, Gajdusek DC, Chase TN, Ikuta F. The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy. Acta Neuropathologica. 88: 122-8. PMID 7985492 DOI: 10.1007/Bf00294504 |
0.33 |
|
| 1994 |
Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Research. 662: 69-74. PMID 7859092 DOI: 10.1016/0006-8993(94)90796-X |
0.316 |
|
| 1994 |
Anderson JJ, Kuo S, Chase TN. Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors. Neuroscience Letters. 176: 264-8. PMID 7830961 DOI: 10.1016/0304-3940(94)90097-3 |
0.345 |
|
| 1994 |
Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 5: 2586-8. PMID 7696610 |
0.34 |
|
| 1994 |
Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology. 44: S15-8. PMID 7519334 |
0.323 |
|
| 1993 |
Papa SM, Engber TM, Boldry RC, Chase TN. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. European Journal of Pharmacology. 232: 247-53. PMID 8385618 DOI: 10.1016/0014-2999(93)90781-C |
0.318 |
|
| 1993 |
Giuffra ME, Sethy VH, Davis TL, Mouradian MM, Chase TN. Milacemide therapy for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 47-50. PMID 8380487 DOI: 10.1002/mds.870080109 |
0.321 |
|
| 1993 |
Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J, Carson RE, Herscovitch P, Chase TN. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 9: 277-91. PMID 8305128 DOI: 10.1038/Npp.1993.64 |
0.311 |
|
| 1993 |
Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology. 43: S23-7. PMID 8264907 |
0.336 |
|
| 1993 |
Anderson JJ, Kuo S, Chase TN, Engber TM. GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo. Neuroscience Letters. 160: 126-30. PMID 8247341 DOI: 10.1016/0304-3940(93)90395-2 |
0.319 |
|
| 1993 |
Giuffra M, Mouradian MM, Davis TL, Ownby J, Chase TN. Dynorphin agonist therapy of Parkinson's disease. Clinical Neuropharmacology. 16: 444-7. PMID 8106151 |
0.316 |
|
| 1993 |
Engber TM, Marin C, Susel Z, Chase TN. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding. European Journal of Pharmacology. 236: 385-93. PMID 8102970 DOI: 10.1016/0014-2999(93)90476-X |
0.376 |
|
| 1993 |
Bravi D, Davis TL, Mouradian MM, Chase TN. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 195-7. PMID 8097280 DOI: 10.1002/Mds.870080214 |
0.417 |
|
| 1993 |
Anderson JJ, Chase TN, Engber TM. Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats. Brain Research. 623: 189-94. PMID 7693302 DOI: 10.1016/0006-8993(93)91426-S |
0.33 |
|
| 1993 |
Boldry RC, Kelland MD, Engber TM, Chase TN. NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens. Brain Research. 600: 331-4. PMID 7679606 DOI: 10.1016/0006-8993(93)91392-6 |
0.38 |
|
| 1992 |
Baronti F, Davis TL, Boldry RC, Mouradian MM, Chase TN. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology. 42: 541-4. PMID 1549214 DOI: 10.1212/Wnl.42.3.541 |
0.346 |
|
| 1992 |
Baronti F, Mouradian MM, Davis TL, Giuffra M, Brughitta G, Conant KE, Chase TN. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Annals of Neurology. 32: 776-81. PMID 1471868 DOI: 10.1002/Ana.410320611 |
0.445 |
|
| 1992 |
Anderson JJ, Chase TN, Engber TM. Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats. Brain Research. 588: 307-10. PMID 1356592 DOI: 10.1016/0006-8993(92)91591-2 |
0.352 |
|
| 1992 |
Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology. 42: 1241-3. PMID 1351273 DOI: 10.1212/Wnl.42.6.1241 |
0.401 |
|
| 1992 |
Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clinical Neuropharmacology. 15: 148-51. PMID 1350513 DOI: 10.1097/00002826-199204000-00009 |
0.398 |
|
| 1991 |
Mouradian MM, Heuser IJ, Baronti F, Giuffra M, Conant K, Davis TL, Chase TN. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 54: 401-5. PMID 1865201 |
0.321 |
|
| 1991 |
Ariano MA, Engber TM, Susel Z, Chase TN. Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy. Experimental Neurology. 112: 112-8. PMID 1826481 DOI: 10.1016/0014-4886(91)90120-2 |
0.311 |
|
| 1991 |
Baronti F, Ruggieri S, Mouradian MM, Bonamartini A, Bocciarelli P, De Pandis MF, Chase TN, Agnoli A. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease]. Rivista Di Neurologia. 61: 210-4. PMID 1813972 |
0.323 |
|
| 1991 |
Mouradian MM, Blin J, Giuffra M, Heuser IJ, Baronti F, Ownby J, Chase TN. Somatostatin replacement therapy for Alzheimer dementia. Annals of Neurology. 30: 610-3. PMID 1789687 DOI: 10.1002/Ana.410300415 |
0.326 |
|
| 1991 |
Baronti F, Conant KE, Giuffra M, Davis TL, Brughitta G, Iadarola MJ, Berrettini WH, Chase TN, Mouradian MM. Opioid peptides in Parkinson's disease: effects of dopamine repletion. Brain Research. 560: 92-6. PMID 1684735 DOI: 10.1016/0006-8993(91)91219-Q |
0.425 |
|
| 1990 |
Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology. 27: 18-23. PMID 2301923 DOI: 10.1002/Ana.410270105 |
0.425 |
|
| 1990 |
Parashos SA, Marin C, Barone P, Kapitzoglou-Logothetis V, Chase TN. Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology. 102: 411-3. PMID 2251338 DOI: 10.1007/Bf02244112 |
0.391 |
|
| 1990 |
Mohr E, Litvan I, Williams J, Fedio P, Chase TN. Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 17: 292-7. PMID 2207883 DOI: 10.1017/S0317167100030596 |
0.308 |
|
| 1990 |
Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (New York, N.Y.). 250: 1429-32. PMID 2147780 DOI: 10.1126/Science.2147780 |
0.306 |
|
| 1990 |
Weick BG, Engber TM, Susel Z, Chase TN, Walters JR. Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration. Brain Research. 523: 16-22. PMID 2119854 DOI: 10.1016/0006-8993(90)91631-P |
0.417 |
|
| 1990 |
Engber TM, Susel Z, Kuo S, Chase TN. Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 10: 3889-95. PMID 1980132 DOI: 10.1523/Jneurosci.10-12-03889.1990 |
0.382 |
|
| 1989 |
Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Annals of Neurology. 25: 523-6. PMID 2774496 DOI: 10.1002/ana.410250521 |
0.326 |
|
| 1989 |
Juncos JL, Engber TM, Raisman R, Susel Z, Thibaut F, Ploska A, Agid Y, Chase TN. Continuous and intermittent levodopa differentially affect basal ganglia function. Annals of Neurology. 25: 473-8. PMID 2774488 DOI: 10.1002/ana.410250509 |
0.365 |
|
| 1989 |
Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. 39: 7-10; discussion 19. PMID 2685653 |
0.342 |
|
| 1989 |
Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, Claus JJ, Fedio P, Chase TN. Clonidine treatment of Alzheimer's disease. Archives of Neurology. 46: 376-8. PMID 2650662 DOI: 10.1001/Archneur.1989.00520400030015 |
0.363 |
|
| 1989 |
Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. European Journal of Pharmacology. 168: 291-8. PMID 2573533 DOI: 10.1016/0014-2999(89)90790-5 |
0.411 |
|
| 1989 |
Parashos SA, Barone P, Marin CA, Paraschos AJ, Kapitzoglou-Logothetis V, Chase TN. Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat. Psychopharmacology. 98: 189-92. PMID 2569216 DOI: 10.1007/Bf00444690 |
0.397 |
|
| 1989 |
Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 631-5. PMID 2567345 DOI: 10.1136/Jnnp.52.5.631 |
0.325 |
|
| 1989 |
Mohr E, Fabbrini G, Williams J, Schlegel J, Cox C, Fedio P, Chase TN. Dopamine and memory function in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 113-20. PMID 2543918 DOI: 10.1002/Mds.870040202 |
0.352 |
|
| 1988 |
Barone P, Tucci I, Parashos SA, Chase TN. Supersensitivity to a D-1 dopamine receptor agonist and subsensitivity to a D-2 receptor agonist following chronic D-1 receptor blockade. European Journal of Pharmacology. 149: 225-32. PMID 3261693 DOI: 10.1016/0014-2999(88)90652-8 |
0.37 |
|
| 1988 |
Braun AR, Chase TN. Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists. European Journal of Pharmacology. 147: 441-51. PMID 3259931 DOI: 10.1016/0014-2999(88)90179-3 |
0.374 |
|
| 1987 |
Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase TN. Cognitive concomitants of dopamine system stimulation in parkinsonian patients. Journal of Neurology, Neurosurgery, and Psychiatry. 50: 1192-6. PMID 3668568 DOI: 10.1136/Jnnp.50.9.1192 |
0.35 |
|
| 1987 |
Tamminga CA, Tanimoto K, Kuo S, Beck M, Chase TN. Central cholecystokinin octapeptide reduces glucose utilization in subcortical but not cortical rat brain. European Journal of Pharmacology. 139: 237-41. PMID 3653246 DOI: 10.1016/0014-2999(87)90257-3 |
0.303 |
|
| 1987 |
Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Annals of Neurology. 22: 475-9. PMID 3435068 DOI: 10.1002/Ana.410220406 |
0.416 |
|
| 1987 |
Tanimoto K, Tamminga CA, Chase TN. Elevation of plasma prolactin concentrations by intravenous SCH 23390 and SKF 38393 in conscious rats. European Journal of Pharmacology. 144: 147-51. PMID 3325296 DOI: 10.1016/0014-2999(87)90513-9 |
0.373 |
|
| 1987 |
Parashos SA, Barone P, Tucci I, Chase TN. Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade. Life Sciences. 41: 2279-84. PMID 3316889 DOI: 10.1016/0024-3205(87)90539-X |
0.368 |
|
| 1987 |
Barone P, Bankiewicz KS, Corsini GU, Kopin IJ, Chase TN. Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology. 37: 1592-5. PMID 3309720 DOI: 10.1212/Wnl.37.10.1592 |
0.307 |
|
| 1987 |
Tanimoto K, Tamminga CA, Chase TN, Nilaver G. Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide. Endocrinology. 121: 127-32. PMID 3297634 DOI: 10.1210/Endo-121-1-127 |
0.312 |
|
| 1987 |
Barone P, Tucci I, Parashos SA, Chase TN. D-1 dopamine receptor changes after striatal quinolinic acid lesion. European Journal of Pharmacology. 138: 141-5. PMID 2957219 DOI: 10.1016/0014-2999(87)90351-7 |
0.389 |
|
| 1987 |
Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science (New York, N.Y.). 236: 719-22. PMID 2953072 DOI: 10.1126/Science.2953072 |
0.408 |
|
| 1987 |
Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. Journal of Neural Transmission. 68: 41-50. PMID 2949059 DOI: 10.1007/Bf01244638 |
0.334 |
|
| 1987 |
Tamminga CA, Tanimoto K, Kuo S, Chase TN, Contreras PC, Rice KC, Jackson AE, O'Donohue TL. PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse (New York, N.Y.). 1: 497-504. PMID 2850626 DOI: 10.1002/Syn.890010514 |
0.35 |
|
| 1986 |
Foster NL, Tamminga CA, O'Donohue TL, Tanimoto K, Bird ED, Chase TN. Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease. Neuroscience Letters. 63: 71-5. PMID 3754039 DOI: 10.1016/0304-3940(86)90015-7 |
0.33 |
|
| 1986 |
Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Archives of Neurology. 43: 659-61. PMID 3524514 DOI: 10.1001/Archneur.1986.00520070017009 |
0.368 |
|
| 1986 |
Braun AR, Chase TN. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. European Journal of Pharmacology. 131: 301-6. PMID 3493161 DOI: 10.1016/0014-2999(86)90588-1 |
0.351 |
|
| 1986 |
Foster NL, Chase TN, Patronas NJ, Gillespie MM, Fedio P. Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography. Annals of Neurology. 19: 139-43. PMID 3485952 DOI: 10.1002/Ana.410190205 |
0.305 |
|
| 1986 |
Tamminga CA, Littman RL, Alphs LD, Chase TN, Thaker GK, Wagman AM. Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology. 88: 387-91. PMID 3083460 DOI: 10.1007/Bf00180843 |
0.315 |
|
| 1986 |
Braun AR, Barone P, Chase TN. Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors. Advances in Experimental Medicine and Biology. 204: 151-66. PMID 2947426 DOI: 10.1007/978-1-4684-5191-7_10 |
0.389 |
|
| 1986 |
Dawson TM, Barone P, Sidhu A, Wamsley JK, Chase TN. Quantitative autoradiographic localization of D-1 dopamine receptors in the rat brain: use of the iodinated ligand [125I]SCH 23982. Neuroscience Letters. 68: 261-6. PMID 2944035 DOI: 10.1016/0304-3940(86)90499-4 |
0.369 |
|
| 1986 |
Ludwig CL, Weinberger DR, Bruno G, Gillespie M, Bakker K, LeWitt PA, Chase TN. Buspirone, Parkinson's disease, and the locus ceruleus. Clinical Neuropharmacology. 9: 373-8. PMID 2873889 DOI: 10.1097/00002826-198608000-00004 |
0.371 |
|
| 1986 |
Barone P, Davis TA, Braun AR, Chase TN. Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions. European Journal of Pharmacology. 123: 109-14. PMID 2872071 DOI: 10.1016/0014-2999(86)90694-1 |
0.423 |
|
| 1985 |
Cohen SL, Knight M, Tamminga CA, Chase TN. A comparison of peripheral and central effects of CCK8 on water-reinforced operant responding. European Journal of Pharmacology. 116: 229-38. PMID 4076337 DOI: 10.1016/0014-2999(85)90157-8 |
0.303 |
|
| 1985 |
Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN, Calne DB. Dystonia: treatment with bromocriptine. Clinical Neuropharmacology. 8: 328-33. PMID 3907823 DOI: 10.1097/00002826-198512000-00003 |
0.333 |
|
| 1985 |
Bruno G, Ruggieri S, Chase TN, Bakker K, Tamminga CA. Caerulein treatment of Parkinson's disease. Clinical Neuropharmacology. 8: 266-70. PMID 3899353 DOI: 10.1097/00002826-198509000-00007 |
0.413 |
|
| 1985 |
Juncos J, Serrati C, Fabbrini G, Chase TN. Fluctuating levodopa concentrations and Parkinson's disease. Lancet. 2: 440. PMID 2863459 DOI: 10.1016/S0140-6736(85)92754-0 |
0.326 |
|
| 1985 |
Massari VJ, Shults CW, Park CH, Tizabi Y, Moody TW, Chronwall BM, Culver M, Chase TN. Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord. Brain Research. 343: 268-74. PMID 2413960 DOI: 10.1016/0006-8993(85)90744-9 |
0.303 |
|
| 1984 |
Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Di Chiro G. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Annals of Neurology. 15: S170-4. PMID 6611118 DOI: 10.1002/Ana.410150732 |
0.305 |
|
| 1984 |
Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, Di Chiro G. Cortical abnormalities in Alzheimer's disease. Annals of Neurology. 16: 649-54. PMID 6335378 DOI: 10.1002/Ana.410160605 |
0.316 |
|
| 1984 |
Foster NL, Newman RP, LeWitt PA, Gillespie MM, Larsen TA, Chase TN. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Annals of Neurology. 16: 505-8. PMID 6149724 DOI: 10.1002/Ana.410160412 |
0.37 |
|
| 1984 |
Foster NL, Newman RP, LeWitt PA, Gillespie MM, Chase TN. Treatment of resting tremor by beta-adrenergic blockade. American Heart Journal. 108: 1173-7. PMID 6148881 DOI: 10.1016/0002-8703(84)90603-3 |
0.337 |
|
| 1984 |
Knight M, Tamminga CA, Steardo L, Beck ME, Barone P, Chase TN. Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin receptors. European Journal of Pharmacology. 105: 49-55. PMID 6092115 DOI: 10.1016/0014-2999(84)90647-2 |
0.311 |
|
| 1983 |
Foster NL, Chase TN, Denaro A, Hare TA, Tamminga CA. THIP treatment of Huntington's disease. Neurology. 33: 637-9. PMID 6221200 DOI: 10.1212/Wnl.33.5.637 |
0.362 |
|
| 1983 |
Cohen SL, Knight M, Tamminga CA, Chase TN. Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy. European Journal of Pharmacology. 83: 213-22. PMID 6129145 DOI: 10.1016/0014-2999(82)90254-0 |
0.307 |
|
| 1983 |
Lewitt PA, Chase TN. ‘On—off’ effects: the new challenge in parkinsonism Trends in Neurosciences. 6: 1-4. DOI: 10.1016/0166-2236(83)90003-6 |
0.312 |
|
| 1981 |
Williams AC, Levine RA, Chase TN, Lovenberg W, Calne DB. CFS hydroxylase cofactor levels in some neurological diseases. Journal of Neurology, Neurosurgery, and Psychiatry. 43: 735-8. PMID 6448917 DOI: 10.1136/Jnnp.43.8.735 |
0.328 |
|
| 1980 |
Beasley BL, Nutt JG, Davenport RW, Chase TN. Treatment with Tryptophan of Levodopa-Associated Psychiatric Disturbances Archives of Neurology. 37: 155-156. PMID 7356421 DOI: 10.1001/Archneur.1980.00500520053008 |
0.309 |
|
| 1980 |
Tamminga CA, Chase TN. Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia. Archives of Neurology. 37: 204-5. PMID 6102461 DOI: 10.1001/Archneur.1980.00500530042004 |
0.379 |
|
| 1979 |
Nutt JG, Rosin A, Chase TN. Treatment of Huntington disease with a cholinergic agonist. Neurology. 28: 1061-4. PMID 154624 DOI: 10.1212/Wnl.28.10.1061 |
0.34 |
|
| 1979 |
Nutt JG, Rosin AJ, Eisler T, Calne DB, Chase TN. Effect of an opiate antagonist on movement disorders. Archives of Neurology. 35: 810-1. PMID 152622 DOI: 10.1001/Archneur.1978.00500360034006 |
0.34 |
|
| 1976 |
Shoulson I, Chase TN. Clonidine and the anti-parkinsonian response to L-DOPA or piribedil. Neuropharmacology. 15: 25-7. PMID 768802 DOI: 10.1016/0028-3908(76)90093-9 |
0.351 |
|
| 1974 |
Chase TN, Woods AC, Glaubiger GA. Parkinson disease treated with a suspected dopamine receptor agonist. Archives of Neurology. 30: 383-6. PMID 4821783 DOI: 10.1001/archneur.1974.00490350041006 |
0.31 |
|
| 1974 |
Chase TN, Balch TS, Jacobowitz DM. Dopamine histofluorescence in post-mortem specimens of human and rat striatum Journal of Psychiatric Research. 11: 281-282. PMID 4461797 DOI: 10.1016/0022-3956(74)90106-X |
0.313 |
|
| 1973 |
Chase TN, Gordon EK, Ng LK. Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid. Journal of Neurochemistry. 21: 581-7. PMID 4270247 DOI: 10.1111/J.1471-4159.1973.Tb06003.X |
0.321 |
|
| 1971 |
Mendell JR, Chase TN, Engel WK. Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa. Archives of Neurology. 25: 320-5. PMID 5110126 DOI: 10.1001/Archneur.1971.00490040046006 |
0.35 |
|
| 1971 |
Chase TN, Breese GR, Gordon EK, Kopin IJ. Catecholamine metabolism in the dog: comparison of intravenously and intraventricularly administered [14C]dopamine and [3H]norepinephrine. Journal of Neurochemistry. 18: 135-40. PMID 5107962 DOI: 10.1111/J.1471-4159.1971.Tb00175.X |
0.3 |
|
| 1970 |
Brody JA, Chase TN, Gordon EK. Depressed monoamine catabolite levels in cerebrospinal fluid of patients with parkinsonism dementia of Guam. The New England Journal of Medicine. 282: 947-50. PMID 5436031 DOI: 10.1056/Nejm197004232821704 |
0.35 |
|
| Show low-probability matches. |